The ability of mitomycin C to inhibit fi broblasts in vitro has prompted its use du ring standard surgica l p rocedu res as a means of preventin g the development of adhes ions and stenos is. We conducted a p rospectiv e study to evaluate the effec tiveness oftopical mitomycin C in mai ntaining an open externa l auditory canal in 6 ears of 4 patients with aural fib rotic atresia who were undergoing nteatoplasty. Durin g the procedure, we appli ed l ml ofmitomycin C (0.4 tug/n il) fo r 4 minutes to the external auditory canal (in 1 case, mitomycin C was reapplied to an ear 1 month later ). Between 3 and /4 months postoperatively, the patency ofthe ear canal was assessed visually and hearin g was evaluated audiomet rica lly.Adequate patency was achieved in5 ofthe 6 ears (83.3%), and the air-bone gap in these 5 ears had improved to 10 dB or less. No postoperative comp lications or senso rineural hearing loss was obse rved. In this vel)' limited number of cases, we fo und that the intraoperati ve use ofmitomycin C app eared to have been helpful in preventing scarring in both conge nital and secondaryfibrotic atresias ofthe external auditory canal. These preliminary results are enco urag ing, and a p rospective, pla cebocontrolled study appe ars to be war ranted.
Introduction
Occlu sion s and clo sur es of the extern al aud itory ca na l are rare and difficult to manage. I Either ca n occur as a co nge nital abn ormalit y-or sec ondary to chro nic ex terna l otitis.>"other d isea ses; " and trauma."Th e primary factors in deciding wh eth er to opera te on co ngenital or acquire d aural atres ias are the seve rity of the hearing impairment and the risk of cho lestea to ma. Som e rep orts of po stoperativ e result s are very enco uraging. 10 Som e autho rs are not satisfied with cla ssic surgi ca l method s for treatin g aura l atres ias, and they favor instead the use of a KTP/S32 laser!' or more exten sive surgery."
Numerou s surg ica l procedures via enda ura l and postauricul ar approac hes have been repo rted .1-12 Accordin g to some of the se reports, the removal of the disea sed sk in from an ex tern al au ditory canal was insuffici ent.P-":" For especially difficult cas es, additional surg ical procedures have been introduced in an effort to prevent abundant growth of gra nulation tissue and sub sequ ent recl osure of the ca na l and co nse que nt conductive hearing loss. Mitomycin C is an antineo plas tic agent produced by the fungus Streptom yces caespitosus . It inhibits DNA and RNA replication, wh ich lead s to a reducti on in protein synthes is and subse que nt ce ll death . In cultured fibroblasts, mitom ycin C is very pot ent in inhibiting mitosis.t-!' For the se reason s, mit omycin C has been used in some ophthalmologic and ENT procedures in an effo rt to control or prevent scarring and stricture.' >' ? Before mitomycin C wa s used in clinical otology, it was tested in se vera l anima l studies as a me an s of pre vent ing ea rly clos ure of myringotornies.P:" Th e promisin g res ults of those experim ent s led to its clinical use in ear surgery in human s.P:"
We conducted a study to ev aluate the pos sib ility of cre atin g a lon g-t erm op en ing in the ex terna l auditory canal of patients w ith aural fibrou s atres ia, and thereb y imp rov e hearin g, by administering topic al mitomy cin C during meatoplasty, the cla ssic surgica l pro cedure for thi s co nditio n. (table I) .
Patients and methods
Aft er an initial clinical evaluation, we orde red computed tomography (CT) of the temporal regi on to ex clude osse- Pt.
3 Table 2 . Preoperative pure-tone thresholds (dB) common despite proper surgical technique.rs-" Several surgical and adj unctive treatments have been introduced to minimize recurrence.1.8.l l.1 2,26 One of these adj unctive treatments is topical mitomycin C. Mitomyci n C was isolated by Wakaki et al in the 1950s from Streptomyces caespitosus?' In 1967, Oboshi et al described both its antimicro bial properties and its suppress ive effec ts on tumor growth."
Ophthalmology. Mitomycin C was used clinically in ophthalmology as a means of preventi ng recurrent pterygium , as reported by Murakami 
Results
Postoperatively, the externa l auditory canal remained open in 5 of the 6 ears (83.3 %). In the 5 ears, visualization of the tympanic membrane was good without the need for spec ial procedures, such as clea ning the external ear canal with instruments. In I of these 5 ears, granulation tissue developed near the tympanic membrane I month postoperatively, and mitomycin C was applied for a second time. The I ear that was not successfully treated had remained open for 2 months; there was no air-bone gap. One month later, the patient returned with a complaint of recurrent hearing loss. Otomicroscopic exa mination revea led that the tympanic memb rane was again covere d with gra nulation tissue.
The mean postoperative air-bone gap had closed to 10dB or less in the 5 successfully opened ears and to within 30 dB in the other ear (table 3) . Bone-conduction thresholds did not change postoperatively in any of the 6 ears.
Discussion
A recurre nce of adhesions and stenoses following treatment of fibrous atresias of the external auditory canal is Volume 84, Number 12 ous atresia of the external auditory canal and to ascer tain the norma l T_a_b_l_e_1_._p_a_t_ie_n_t_ch_a_r_a_ct_e_r_i_st_i_cs _ status of the middle ear cavity. CT Pt . Ag e/ s ex detected no signs of osseo us atresia or changes in the tympanic cavity or ossicles.
We then performed audiome try to measure air-and bone-conduction thres holds, and we used these data to calculate the air-bone gap in accor dance with guidelines pub lished by the Amer ican Academy of Otolaryngology-Head Neck Surgery (table 2) . 24 The pure-tone averages for air-and bone-conduction thresholds were obtained at 0.5, 1.0, 2.0, and 3.0 kHz.
All meatoplasties were undertaken via an endaura l approach. At the time of surgery, all external auditory cana ls were dry, and no signs of necrotizing ("ma lignant") external otitis were evident. The meatal skin flap was elevated and the posterior portion of the anulus tympan icus was expose d. After the tympanic memb rane was visualized, the fibrous tissue was carefully excise d from the external auditory canal. The tympanic memb rane was covered with a thin layer of dry Gelfoam to protect it from the topical mitomy cin C. Then I ml of mitomycin C in a concentration of 0.4 mg/ml was applied for 4 minut es to the area where the fibrous tissue had been located. Local skin flaps were used to cove r the skin defects.
The length of postoperative follow-up ranged from 3 'to 14 month s (mean: 7.2). The external auditory cana l was exa mined microscopically at each follow-up visit. Postoperative audiometry was performed at each patient 's final follow-u p visit. Banthia and Selesnick used 0.5 mg/ml for 5 minutes for preventing scar formation in the postsurgical ear canal." During endolymphatic sac surgery, Huang used I mg/ml for 5 minutes." Jassiretal described a dose-response curve with doses up to 0.4 mg/ml for 10 minutes in prolonging myringotomy patency; according to that study, a higher dose (2.0 mg/ml) did not appear to prolong patency but was associated with an increase in otorrhea and possible ototoxicity." In our study, I ml of 0.4 mg/ml of mitomycin C in saline for 4 minutes yielded satisfactory results. Meniere 's disease was first described by Yazawa et al in 1999. 20 They used intraoperative topical mitomycin C in 14 patients with Meniere 's disease who were undergoing endolymphatic sac mastoid shunt surgery. Patients were followed for more than 6 months. None of these patients experienced vertigo, although some did complain of slight dizziness. In 2002 , Huang reported the outcomes of 103 patients with Men iere's disease who had been treated with endolymphatic sac surgery and topical mitomycin C. 35 This group was compared with a control group of 109 patients with Meniere's disease who underwent the same surgery without the drug . The mitomycin C group experienced a significantly greater improvement in hearing and no recurrences.
During the past few years , several reports of the effects of mitomycin C on the tympanic membrane and skin have appeared. The maintenance of myringotomy patency was reported in rat tympanic membranes by Yucel in 2000. 36 Similar results in guinea pigs were soon reported by Estrem with mitomycin C in preventing seal' formation in tympanic cavities during surgery on patients with suppurative otitis media." The same year, however, Banthia and Selesnick reported that mitomycin C was not effective in preventing the formation of recurrent granulation tissue following canaloplasty in 6 patients." Likewise, in 2004, D'eredita reported that mitomycin C was no more effective than placebo during diode laser myringotomy on both ear s in 15 children.P In the latter study, mitomycin C was applied to the right ear of each patient and saline to the left ear. After 3 to 4 months of follow-up , no difference in the duration of patency was observed between the 2 groups.
Despite its rarity, fibrous atresia of the external auditory canal has been well described by Declau Good meatoplasty results can be obtained in cases where chronic external otitis primarily affects the cartilaginous part of the external auditory canal ." In these cases , an M meatoplasty is usually sufficient. In 2002, Cremers reviewed surgical outcomes in 12 series of patients with acquired aural atresia and reported promising results. III Surgical results are not always as good in other types of aural atresia.
In the patient in our study who had congenital fibrous administer ing mitomyci n C for myringotomy patency, and they detected no ototoxic ity." Ca nkaya et al performed light and elec tro n microscopic studies of the inner ea rs of 30 guinea pigs after applying topic al mitomycin C to their tymp anic ca vities; aga in, no toxic effects on the inner ear were observed." Likewise, we detected no damage to the inner ear as determined by pure -tone audiometry.
In conclu sio n, our study of a limited number of ears showed that a co nservative surgical approach combined with top ical application of mitomycin C can be a safe and successful method of trea ting fibrous atres ia of the externa l auditory ca nal.
